A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Study Number

3612823

Phase

Age Group

Adult

Principal Investigator

Purpose

The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).

Check your eligibility for this trial

Check now

Full Title

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary
Efficacy of Arlocabtagene autoleucel (BMS-986393) in Novel Combinations in Participants with Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose…

ClinicalTrials.Gov ID

NCT06121843

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.